Literature DB >> 11195042

Aldosterone in renal disease.

T H Hostetter1, M E Rosenberg, H N Ibrahim, I Juknevicius.   

Abstract

Blockade of the renin-angiotensin-aldosterone system has proved effective in retarding the progression of renal disease in the remnant kidney model, as well as other experimental diseases, and most importantly, in a range of progressive human renal diseases. Attention has focused on the role of angiotensin II in propagating progression both by its hemodynamic and non-hemodynamic actions. Recent evidence, predominantly in the remnant kidney model, indicates that the drugs used to block this hormone system, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, also lower aldosterone levels. Aldosterone as well as angiotensin II thus appears to be instrumental in sustaining the hypertension and fibroproliferative destruction of the residual kidney.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11195042     DOI: 10.1097/00041552-200101000-00016

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  10 in total

1.  Effect of aldosterone and its antagonist on the expression of PAI-1 and TGF-β1 in rat hepatic stellate cells.

Authors:  Shenglan Wang; Zhaojie Zhang; Xinyan Zhu; Huimin Wu; Hengjun Gao; Changqing Yang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression.

Authors:  Er-Liang Kong; Jin-Min Zhang; Ni An; Yong Tao; Wei-Feng Yu; Fei-Xiang Wu
Journal:  J Cell Commun Signal       Date:  2018-06-07       Impact factor: 5.782

Review 3.  Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.

Authors:  Mark A Perazella; John F Setaro
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

Review 4.  Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Wendy B Bollag
Journal:  J Endocrinol       Date:  2016-12-02       Impact factor: 4.286

5.  Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.

Authors:  Tetsuo Nishikawa; Yoko Matsuzawa; Sachiko Suematsu; Jun Saito; Masao Omura; Tomoshige Kino
Journal:  Arzneimittelforschung       Date:  2010

6.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

Review 7.  Hypertensive renal damage: insights from animal models and clinical relevance.

Authors:  Karen A Griffin; Anil K Bidani
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

8.  VLDL-activated cell signaling pathways that stimulate adrenal cell aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Maribeth H Johnson; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2016-05-21       Impact factor: 4.102

9.  Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.

Authors:  Junki Morino; Keiji Hirai; Shohei Kaneko; Saori Minato; Katsunori Yanai; Yuko Mutsuyoshi; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Taro Hoshino; Susumu Ookawara; Kazuo Hara; Yoshiyuki Morishita
Journal:  CEN Case Rep       Date:  2019-01-20

10.  Vascular aldosterone production at the pre-diabetic stage of young Otsuka Long-Evans Tokushima Fatty (OLETF) rats, compared with Long-Evans Tokushima Otsuka (LETO) rats.

Authors:  Yoko Matsuzawa; Sachiko Suematsu; Jun Saito; Masao Omura; Tetsuo Nishikawa
Journal:  Molecules       Date:  2013-12-13       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.